Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
CNTB Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Connect Biopharma Holdings LimitedNASDAQ: CNTB
Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025
Stock-based compensation declines year over year
Q4 FY2025 stock-based compensation of $917K fell 81.2% year over year. Over 3 fiscal years it compounded at +54.6% a year.
Context
- Stock-based compensation amounted to 5821.9% of revenue in FY2025, up 5796.0 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 3.73M USD
- Year-over-year change
- -44.6%
- 4-year CAGR
- +27.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.73M | -44.6% |
| FY2024 | 2024-12-31 | 6.73M | +106.4% |
| FY2023 | 2023-12-31 | 3.26M | +223.1% |
| FY2022 | 2022-12-31 | 1.01M | -28.5% |
| FY2021 | 2021-12-31 | 1.41M | — |
Stock-Based Compensation vs competitors
How CNTB compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -44.6% is the 5th highest of 8, against a peer median of -16.6%.
- Stock-based compensation amounts to 5821.9% of revenue for CNTB, versus a peer median of 401.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.03M USD | -58.5% | -18.9% | 10.1% | |
| LTM Mar 2026 | $7.69M USD | -12.5% | +2.7% | 768.9% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $6.36M USD | -16.6% | +1.2% | — |
| FY2025 | $3.73M USD | -44.6% | +54.6% | 5821.9% | |
| LTM Mar 2026 | €2.48M EUR | -152.9% | — | 8455.2% | |
| LTM Mar 2026 | $2.41M USD | -6.9% | -9.8% | 33.9% | |
| LTM Mar 2026 | $1.45M USD | +61.5% | +10.9% | — | |
IMAImageneBio Inc | LTM Mar 2026 | $1.39M USD | -67.0% | +26.9% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $638K USD | — | — | — |
| Peer median (excluding CNTB) | — | -16.6% | +1.9% | 401.4% | |
Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (204.94M) | (116.12M) | (59.38M) | (15.63M) | (55.48M) |
| Depreciation & Amortization | 640.98K | 1.01M | 988K | 660K | 704K |
| Deferred Income Tax | 106.37M | 3.37M | 0 | 0 | 0 |
| Stock-Based Compensation | 1.41M | 1.01M | 3.26M | 6.73M | 3.73M |
| Change in Working Capital | 3.27M | 7.16M | 9.49M | (15.49M) | 580K |
| Accounts Receivables | (2.53K) | 3.37K | 1.04M | (789K) | 776K |
| Inventory | 2.53K | (3.37K) | 0 | 0 | 0 |
| Accounts Payables | 8.89M | 375.66K | (4.28M) | (1.87M) | 1.62M |
| Other Working Capital | (5.62M) | 6.78M | 12.72M | (12.83M) | (1.82M) |
| Other Non-Cash Items | 6.91K | (1.35M) | (2.28M) | 118K | (736K) |
| Operating Cash Flow | (85.57M) | (99.27M) | (47.93M) | (23.61M) | (51.21M) |
| Capital Expenditures | (7.46M) | (4.28M) | (294K) | (750K) | (434K) |
| Acquisitions (Net) | 47.74K | 79.16K | 2.94M | 0 | 0 |
| Purchases of Investments | (17.98M) | (113.7M) | (32.6M) | (15.45M) | (30.47M) |
| Sales of Investments | 20.1M | 34.54M | 105.19M | 12.63M | 39.95M |
| Other Investing Activities | (47.74K) | (79.16K) | (84K) | 123K | 775K |
| Investing Cash Flow | (5.34M) | (83.44M) | 75.16M | (3.45M) | 9.82M |
| Debt Repayment | (126K) | (222K) | (290K) | 0 | 0 |
| Common Stock Issued | 219.99M | 18K | 44K | 227K | 1.09M |
| Common Stock Repurchased | (566K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (19.12M) | 119K | 0 | 0 | 0 |
| Financing Cash Flow | 206.66M | (91.29K) | (246K) | 227K | 1.09M |
| Effect of Forex Changes | (6.34M) | 13.87M | 18K | (595K) | 408K |
| Net Change in Cash | 109.42M | (168.93M) | 27M | (27.43M) | (39.89M) |
| Free Cash Flow | (93.03M) | (103.55M) | (48.22M) | (24.36M) | (51.64M) |
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.